SeaStar Medical Holding Corp (ICU) — Titan Protect Analysis

ICU

SeaStar Medical Holding Corp

Healthcare · ·

$2.94

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$14M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.37

Based on estimated future earnings — lower means cheaper

Rev Growth

+68.9%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-302.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.00

+240% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 2 analysts covering this stock

About SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due

https://seastarmedical.com

Country: United States Employees: 17 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.458

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0819

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.828

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-81.4%

Historical annualised return based on price data

Max Drawdown

-98.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$13.00

77% below the year high

52W Low

$2.07

42% above the year low

Avg Volume

138,836

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.38

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

4.53

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

93.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-727.9%

Profit from core operations before interest and tax

Free Cash Flow

$-9,533,750

Negative — the business is spending more than it generates

Revenue (TTM)

$1M

Total revenue over the last 12 months

Net Income

$-11,899,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$12.00

Target Median

$10.00

Target Low

$8.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go